Cost-effectiveness of prenatal screening for thalassaemia in Hong Kong

Prenatal Diagnosis

Volumn 24, Issue 11, 2004, Pages 899-907

  Leung, K Y ^a   Lee, C P ^a   Tang, M H Y ^a   Lau, E T ^a   Ng, L K L ^a   Lee, Y P ^a   Chan, H Y ^a   Ma, E S K ^a   Chan, Vivian ^a  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Cost effectiveness; Hong Kong; Prenatal screening; Thalassaemia

Indexed keywords

ABORTION; ADULT; ALPHA THALASSEMIA; BETA THALASSEMIA; CALCULATION; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC IMAGING; ECHOGRAPHY; FEMALE; HEALTH CARE COST; HEALTH PROGRAM; HOMOZYGOSITY; HONG KONG; HUMAN; MONEY; PRENATAL SCREENING; PRIORITY JOURNAL; RETROSPECTIVE STUDY; REVIEW; THALASSEMIA MAJOR;

ALPHA-THALASSEMIA; BETA-THALASSEMIA; COST-BENEFIT ANALYSIS; DECISION TREES; FEMALE; HONG KONG; HUMANS; MEDICAL RECORDS; OUTCOME ASSESSMENT (HEALTH CARE); PREDICTIVE VALUE OF TESTS; PREGNANCY; PRENATAL DIAGNOSIS; RETROSPECTIVE STUDIES; THALASSEMIA;

EID: 9644252847     PISSN: 01973851     EISSN: None     Source Type: Journal    
DOI: 10.1002/pd.1035     Document Type: Review

References (25)

1. Beris P, Darbellay R, Extermann P. 1995. Prevention of β-thalassaemia major and Hb Bart's hydrops fetalis syndrome. Semin Hematol 32: 244-261.
2. Chan LC, Ma SK, Chan AYY, et al. 2001. Should we screen for globin gene mutations in blood samples with mean corpuscular volume (MCV) greater than 80fL in areas with a high prevalence of thalassaemia? J Clin Pathol 54: 317-320.
3. Chan V, Yip B, Lam YH, Tse HY, Wong HS, Chan TK. 2001. Quantitative polymerase chain reaction for the rapid prenatal diagnosis of homozygous alpha-thalassaemia (Hb Barts hydrops fetalis). Br J Haematol 115: 341-346.
4. Cronin EK, Normand C, Henthorn JS, Graham V, Davies SC. 2000. Organisation and cost-effectiveness of antenatal haemoglobinopathy screening and follow up in a community-based programme. Br J Obstet Gynaecol 107: 486-491.
5. Fleming AF, Lynch W. 1969. Beta-thalassaemia minor during pregnancy with particular reference to iron status. Br J Obstet Gynaecol 76: 451-455.
6. Ghosh A, Tang MHY, Lam YH, Fung E, Chan V. 1994. Ultrasound measurement of placental thickness to detect pregnancies affected by homozygous α-thalassaemia-1. Lancet 344: 988-989.
7. Ghosh A, Woo JSK, Wan CW, et al. 1985. Evaluation of a prenatal screening procedure for β-thalassaemia carriers in a Chinese population based on the mean corpuscular volume (MCV). Prenat Diagn 5: 59-65.
8. Ginsberg G, Tulchinsky T, Filon D, Goldfarb A, Abramov L, Rachmilevitz B. 1998. Cost-benefit analysis of a national thalassaemia prevention programme. J Med Screen 5: 120-126.
9. Ko TM, Tseng LH, Hwa HL. 1997, et al. Misdiagnosis of homozygous alpha-thalassaemia 1 may occur if polymerase chain reaction alone is used in prenatal diagnosis. Prenat Diagn 17: 505-509.
10. Lam YH, Ghosh A, Tang MH, Chan V. 1997a. The risk of alpha-thalassaemia in offspring of beta-thalassaemia carriers in Hong Kong. Prenat Diagn 17: 733-736.
11. Lam YH, Ghosh A, Tang MHY, Lee CP, Sin SY. 1997b. Early ultrasound prediction of pregnancies affected by homozygous α-thalassaemia-1. Prenat Diagn 17: 327-332.
12. Lam YH, Tang MHY, Lee CP, Tse HY. 1999. Prenatal ultrasonographic prediction of homozygous type 1 alpha-thalassaemia at 12 to 13 weeks of gestation. Am J Obstet Gynecol 180: 148-150.
13. Lau YL, Chan LC, Chan YY, et al. 1997. Prevalence and genotypes of alpha- and beta-thalassemia carriers in Hong Kong-implications of population screening. N Engl J Med 336: 1314-1316.
14. Lee AC, Ha SY, Wong KW, et al. 1998. Prevention of beta-thalassemia major by antenatal screening in Hong Kong. Pediatr Hematol Oncol 15: 249-254.
15. Li AMC. 1990. Haematological findings in Hong Kong Chinese with β-thalassaemia trait. J Hong Kong Med Assoc 42: 134-136.
16. Liang ST, Wong VC, So WW, Ma HK, Chan V, Todd D. 1985. Homozygous alpha-thalassaemia: clinical presentation and management. A review of 46 cases. Br J Obstet Gynaecol 92: 680-684.
17. Ma ESK, Chan AYY, Ha SY, Lau YL, Chan LC. 2001. Thalassaemia screening based on red cell indices in the Chinese. Haematologica 86: 1286-1287.
18. Modell B, Harris R, Lane B, et al. 2000. Informed choice in genetic screening for thalassaemia during pregnancy: audit from a national confidential inquiry. Br Med J 320: 337-341.
19. Modell B, Petrou M, Layton M, et al. 1997. Audit of prenatal diagnosis for haemoglobin disorders in the United Kingdom: the first 20 years. Br Med J 315: 779-784.
20. Modell B, Petrou M, Ward RHT, et al. 1985. Effect of fetal diagnostic testing on the birth-rate of thalassaemia in Britain. Lancet 2: 1383-1386.
21. Neuenschwander H, Modell B. 1997. The process of antenatal sickle cell screening at a north London hospital. Br Med J 315: 784-785.
22. Orofino MG, Argiolu F, Sanna MD, et al. 2003. Fetal HLA typing in β thalassaemia: implications for haematopoietic stem-cell transplantation. Lancet 362: 41-42.
23. Ostrowsky JT, Lippman A, Scriver CR. 1985. Cost-benefit analysis of a thalassaemia disease prevention program. Am J Public Health 75: 732-736.
24. Sin SY, Ghosh A, Tang LCH, Chan V. 2000. Ten years' experience of antenatal mean corpuscular volume screening and prenatal diagnosis for thalassaemias in Hong Kong. J Obstet Gynecol Res 26: 203-208.
25. World Health Organisation. 1982. Report on the community control of hereditary anemia. Memorandum from WHO meeting. Bull World Health Organ 61: 63-80.